Am J Cardiol. 2003 Mar 6;91(5A):11C-17C; discussion 17C-19C.
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG.
Department of Pathological Biochemistry, Royal Infirmary, University of Glasgow, Scotland, United Kingdom. jshepherd@gri-biochem.org.uk
Both the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III and the Second Joint Task Force of European Societies guidelines have established low-density lipoprotein (LDL) cholesterol goals for lipid-lowering treatment to reduce the risk of coronary artery disease. Data from 3 trials that compared rosuvastatin 10 mg (n = 389) with atorvastatin 10 mg (n = 393) and 2 trials that compared rosuvastatin 10 mg (n = 226) with pravastatin 20 mg (n = 252) and simvastatin 20 mg (n = 249) were pooled separately to compare the achievement of LDL cholesterol goals over 12 weeks of treatment in hypercholesterolemic patients. Noncomparative pooling of rosuvastatin 10 mg results from all 5 trials (n = 615) showed that 80% achieved NCEP ATP III goals and 81% achieved the European goal of <3.0 mmol/L. Compared with atorvastatin 10 mg, significantly more patients treated with rosuvastatin 10 mg achieved their ATP III (76% vs 53%) and European (82% vs 51%) goals (p <0.001). Also, in comparisons with simvastatin 20 mg and pravastatin 20 mg, 86% of patients treated with rosuvastatin 10 mg achieved ATP III goals, compared with 64% of simvastatin-treated patients and 49% of pravastatin-treated patients (p <0.001). The proportions of patients who achieved the European goal were 80%, 48%, and 16% for rosuvastatin 10 mg, simvastatin 20 mg, and pravastatin 20 mg, respectively, in this comparison (all p <0.001). A total of 71% of patients treated with rosuvastatin 10 mg who had triglyceride levels > or =200 mg/dL met both their LDL cholesterol and their non-high-density lipoprotein cholesterol goals.
Please click on the required question.
- 1 What will happen to me at my menopause?
- 2 Why does nature put women through the menopause?
- 3 Is life-expectancy changing?
- 4 What happens to my reproductive hormones at the menopause?
- 5 What non-hormonal changes occur at the menopause?
- 6 What problems might I have as a result of my menopause?
- 7 When am I likely to reach my menopause?
- 8 What is a premature menopause?
- 9 What are hot flushes and will HRT reduce them?
- 10 What causes hot flushes and night sweats?
- 11 Can my bladder problems be related to the menopause?
- 12 Can the menopause be associated with psychological problems.
- 13 How long can my menopausal (climacteric) symptoms last?
- 14 Is there a test that will accurately determine when my menopause has occurred?
- 15 Is it normal to experience heavy periods before the menopause?
- 16 How are heavy periods around the time of the menopause treated?
- 17 Is there a need to investigate vaginal bleeding after the menopause (postmenopausal bleeding)?
- 18 What could be the cause of vaginal bleeding after the menopause?
- 19 What is atrophic vaginitis?
- 20 What local genital symptoms can be associated with the menopause?
- 21 I have gone through the menopause and now have some bleeding (postmenopausal bleeding PMB). What will my gynaecologist wish to do?
- 22 Could I have any other long-term medical problems resulting from my menopause?
- 23 What is coronary heart disease?
- 24 What is osteoporosis?
- 25 Where else can I obtain further information?
- 26 Could I have some recommended menopause support groups.
Thank you for choosing to visit us.
This is the personal website of David A Viniker MD FRCOG, Consultant Obstetrician and Gynaecologist at Whipps Cross University Hospital, London - Specialist Interests - Reproductive Medicine including Infertility, PCOS, PMS, Menopause and HRT.
I do hope that you find the answers to your women's health questions in the patient information and medical advice provided.
